AB ABT Abbott Laboratories Loading... : Bullish and Bearish Analyst Opinions

Abbott Laboratories raised its full-year EPS guidance on strong medical device sales and margin expansion, but the neutral Quant rating and declining diagnostics segment keep the outlook balanced.

Buy ABT on near-term momentum continuation; Cramer expects further upside support following a strong up day, though no specific fundamental catalyst is cited.

Abbott Laboratories raised its 2026 profit guidance after a stronger-than-expected second quarter driven by improved performance across most of its business lines.

Abbott reported strong second-quarter 2026 results with accelerating sales growth, margin expansion, and raised full-year guidance driven by momentum across diagnostics, nutrition, and medical devices.

Abbott Laboratories shares extended their gain to 14 percent, marking the largest single-day increase since 2002.

Abbott Laboratories shares surged to a session high of 11 percent, marking their largest single-day gain since 2020.

Abbott Laboratories shares extended gains to 5.7 percent after the company raised its full-year guidance.

US pre-market movers show mixed sector action with TSM down on capex hike despite strong results, UAL lower on light guidance, JBHT up on earnings beat, ATAI surging on LLY acquisition, UNH and ABT rising on strong earnings and outlook, DSGR jumping on buyout, and LULU falling on a Truist downgrade.

The author provides a comprehensive macro and market brief highlighting geopolitical escalation, consumer deterioration, and technical fragility from gamma expiry and buyback blackout without stating any personal positions or forward calls.

Abbott reports second quarter sales of 12.6 billion dollars beating the IBES estimate of 12.50 billion dollars and maintains its full year sales growth outlook of 6.5 to 7.5 percent.

Abbott Labs reported Q2 2026 adjusted EPS of $1.31 beating estimates and raised its full-year adjusted EPS guidance range.

Abbott Labs reports Q2 2026 adjusted EPS of $1.31 beating estimates and raises full-year adjusted EPS guidance to a range of $5.45 to $5.60.

AlphaSense promotes its real-time earnings call coverage platform ahead of earnings season, listing major companies reporting next week.

Trump's DOJ dropped a criminal probe into Abbott over a baby formula plant while Trump purchased up to 500,000 dollars of Abbott stock two months prior.

Premarket movers report shows mixed trading across major stocks with job cuts at Microsoft, analyst upgrades for Abbott and Grindr, downgrades for Dow, and partnership news for Bloom Energy.

The U.S. Justice Department has closed its criminal investigation into Abbott Laboratories' baby formula plant and will instead pursue civil penalties.

Long medtech and digital health names as rising semiconductor content in medical devices drives growth in imaging, monitoring, robotics, and wearables.

Author’s grandparents rely on Abbott’s medication and nutritional products, suggesting strong brand stickiness. Price target of sub-$75 creates a risk/reward entry point for a defensive healthcare name. Buy on pullback to $75 or below as a long-term hold due to durable consumer demand. Regulatory changes, generic competition, or macro downturn delaying recovery.

The post cites a forward P/E of ~14 (compressed), FCF/share of $4.24, 3% dividend yield, ~0.75% buyback potential, 11.5% organic growth, and multiple insider purchases between $91–$108. This data suggests the market underestimates ABT’s intrinsic value. A reversion to a P/E of 19–20 would yield 35–43% price appreciation, plus dividends and buybacks, making the risk/reward asymmetric. A long position in ABT offers a margin of safety with a downside floor near the current PE (~13–14) and upside from multiple expansion, organic growth, and shareholder returns. Higher debt from the Exact Sciences acquisition could pressure margins or delay deleveraging; a recession or regulatory headwind could compress organic growth; the compressed PE may persist if sentiment remains negative.

Watch ABT; stable medical diagnostics with no major catalyst from this read-through; neutral read.

ABT trades at a 16x EV/EBITDA multiple, its cheapest in years, while being a "Dividend King" with a healthy balance sheet and dominant, recession-resistant segments (Medical Devices, Pharmaceuticals). The market is overly punishing the stock for short-term issues (consumer pushback in Nutrition, post-pandemic Diagnostics decline), creating a valuation gap for a stable, growing company. ABT is a high-quality stock that is a buy for long-term value and dividend growth investors. Ongoing baby formula lawsuits harming the Nutrition segment, and the large acquisition/ integration of Exact Sciences failing to stabilize the Diagnostics segment.

Short ABT as a mild flu season has directly hurt sales, prompting a lowered company outlook, indicating near-term earnings pressure.

ABT trades at 18x forward P/E, is growing mid-single digits, pays a >2.5% dividend, and recently made a $21B acquisition in colorectal testing. The author sees this combination of valuation, growth, yield, and strategic expansion as creating a value investment opportunity. The post implies a long-term buy-and-hold investment in a diversified healthcare leader. Acquisition integration risk, slower-than-expected growth, multiple compression if earnings disappoint, or broader healthcare sector headwinds.

Abbott Laboratories faces negative sentiment as a prominent investor expresses clear dissatisfaction with the stock's performance.

Abbott Labs needs convincing catalysts.